Saving changes...

Done

Error

Feline Vaccine-Associated Sarcomas: Myth or Reality?

Feline Vaccine-Associated Sarcomas: Myth or Reality?

Feline Vaccine-Associated Sarcomas: Myth or Reality?

Philip Bergman, DVM, MS, PhD, DACVIM/Oncology
Philip Bergman, DVM, MS, PhD, DACVIM/Oncology
on behalf of American Association of Feline Practitioners

$ FREE $ FREE $ FREE

$ 20.00 $ 20.00 $ 20.00

$ FREE $ FREE $ FREE
$ 20.00 $ 20.00 $ 20.00
Normal Price: FREE $ 20.00

Views: 317

Launch date: 10 Aug 2016

Expiry Date: 01 Aug 2018

Last updated: 17 Dec 2016

Review: (4 comments)

Ref.: 164658

Duration: 1h 0m
Feline Vaccine-Associated Sarcomas: Myth or Reality?

Latest User Comments

Bill Hah (4 Dec 2016)
it is very informative and educational. the lecture explained the newer trend of VAS and threapy modality.
Dr Angela Schmitt DVM (19 Nov 2016)
informative and applicable
Dr Robert Stein DVM (12 Nov 2016)
Very nicely done. Easy to listen to.

E-learning Availability

This e-learning is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This e-learning is no longer available. You will need to repurchase if you wish to take the e-learning again.

I would like to...

Exam is embedded in the e-learning
No Exam Available

Description

Fibrosarcomas are relatively common in the cat. It is of utmost importance in cats to differentiate vaccine or injection site-associated sarcoma (VAS) from non-vaccine-associated sarcoma as the prognosis and treatments are vastly different. Emphasis will be placed on the history, etiology, diagnosis, prognosis, and therapy of cats with VAS.

Objectives

Objective 1
Develop an appreciation for the history/timeline and development of feline vaccine-associated and non-vaccine-associated sarcomas.
Objective 2
Develop an appreciation for the studies in veterinary literature for and against an adjuvant association with feline vaccine-associated sarcoma.
Objective 3
Better understand and utilize the latest diagnostics for cats with vaccine-associated sarcoma.
Objective 4
Better understand and utilize the latest treatments for cats with vaccine-associated sarcoma.
Philip Bergman, DVM, MS, PhD, DACVIM/Oncology

Author Information Play Video Bio

Philip Bergman, DVM, MS, PhD, DACVIM/Oncology
on behalf of American Association of Feline Practitioners

Dr. Bergman is the Director of Clinical Studies for VCA. He is the principal veterinary investigator for the recently fully licensed canine melanoma vaccine (Oncept). Dr. Bergman is an adjunct faculty member of the Memorial Sloan-Kettering Cancer Center. Prior to Dr. Bergman joining VCA, he served as the Chief Medical Officer for BrightHeart Veterinary Centers from July 2007 to August 2011, and from 1999 – June 2007 he was the head of the Donaldson-Atwood Cancer Center at AMC. After finishing veterinary school from Colorado State in 1990, he was an intern at Kansas State (1990-1991) and returned to CSU for his medical oncology residency (1991-1994) and then completed a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (1994-1999). He was previously Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society.

Current Accreditations

This e-learning has been certified by or provided by the following Certified Organization/s:

  • American Association of Veterinary State Boards (RACE)
  • 1.00 Hours -
    Exam Attempts: 3
    -
    Exam Pass Rate: 70
  • New York State Board of Veterinary Medical Examiners
  • 1.00 Hours

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

The following disclosures are related to the presentation:

Sponsor: Merial
Employee: VCA
Grants/Research contracts: Zoetis & Merial
Consulting:
Direct and/or through trial design/implementation:
• Zoetis, BIVI, Merial, Abbott, Elanco, Virbac, Aratana, MBF Therapeutics, Regeneus, AB Science, Bayer, Oasmia, Royal Canin, Ceva, Purina, Kindred Bio, Merck AH, Plumbline Life Sciences
Investments:
Stock Ownership - Aratana, Zoetis, Heska
Minority Royalty Stream – Merial
Oncept® & Xenogeneic DNA Patent with MSKCC

I would like to...

Exam is embedded in the e-learning
No Exam Available

Examine E-learning to add to your Portal

Back to examine Page

E-learning Accepted


This e-learning has already been examined and was accepted to be added to the NAFV CE Pool. The author has been notified. Go to Manage E-learning to view the e-learning.

Examine E-learning to add to your Portal

Back to examine Page

E-learning Rejected


This e-learning has already been examined.

This e-learning was rejected for the following reason:

The author has been notified

Examine E-learning to add to your Portal

Back to examine Page

E-learning Expired


The e-learning has expired.

Loading...


Saving changes...

Done

Error